Loading
Screening 424 women with ER-negative breast cancer found androgen receptor in 12%; the prostate drug bicalutamide held the disease stable for six months in 19% of them, the first clinical proof that the LAR subtype can be treated through its receptor.
TBCRC 011 tested bicalutamide 150 mg daily in ER/PgR-negative advanced breast cancer with central AR immunohistochemistry (over 10% nuclear staining positive). Of 424 patients screened, 12% were AR-positive. The six-month clinical benefit rate was 19% (95% CI 7 to 39) and median progression-free survival 12 weeks; no grade 4 or 5 treatment-related events occurred.
It fixes the AR-positive share of ER-negative disease at about one in eight and shows anti-androgens give modest, non-toxic benefit, the rationale for enzalutamide and later CDK4/6 and PI3K combinations in LAR tumours.
Shares Androgen receptor signalling, Androgen receptor, Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Sara M. Tolaney, Clinical Cancer Research, Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Bicalutamide, Metastatic triple-negative breast cancer.
Shares Bicalutamide, Androgen receptor, Triple-negative breast cancer (TNBC).
Shares Sara M. Tolaney, Immunohistochemistry (IHC), Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Bicalutamide, Androgen receptor, Triple-negative breast cancer (TNBC).
Shares Clinical Cancer Research, Androgen receptor signalling, Androgen receptor.
Shares Androgen receptor signalling, Immunohistochemistry (IHC), Androgen receptor.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/